Amphastar pharmaceuticals inc AMPH.US 總覽分析
)AMPH 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面獲得最高評分，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
AMPH 近期報酬表現
0.95%
Amphastar pharmaceuticals inc
4.57%
同產業平均
3.26%
S&P500
與 AMPH 同產業的標的表現
- IBO Impact biomedical inc價值 -趨勢 2 分波段 4 分籌碼 -股利 1 分查看更多
AMPH 公司資訊
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.